CiMaas BV announces that it entered into a research collaboration with East Ocyon Bio, located in Gurugram, Haryana, India, an innovative company dedicated to developing optimally engineered natural killer (NK) cell and gamma delta T cell therapies to cure patients with cancer and autoimmune diseases.
Under the agreement, East Ocyon Bio will start testing the F012 feeder cell line created by CiMaas to support (CAR)-NK cell expansion from peripheral blood. East Ocyon Bio is the first partner in India using F012 feeder cells in their process with peripheral blood derived NK cells and is a validation by others of our techniques. Moreover, it will enable CiMaas to access the Indian market with innovative treatments for cancer patients and autoimmune diseases.